Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RAVULIZUMAB vs REGADENOSON: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

RAVULIZUMAB vs REGADENOSON: Safety Overview

Metric RAVULIZUMAB REGADENOSON
Total FAERS Reports 118 3,071
Deaths Reported 11 84
Death Rate 9.3% 2.7%
Hospitalizations 89 321
Average Patient Age 48.4 yrs 68.1 yrs
% Female Patients 56.3% 58.6%
FDA Approval Date N/A Apr 10, 2008
Manufacturer Alexion Pharmaceuticals Inc. Apotex Corp.
Route INTRAVENOUS INTRAVENOUS
Marketing Status N/A Prescription